Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie for å vurdere effektiviteten og sikkerheten til Ublituximab + Umbralisib med eller uten Bendamustine og Umbralisib alene hos pasienter med tidligere behandlet non-Hodgkins lymfom (UNITY-NHL)

20. juli 2022 oppdatert av: TG Therapeutics, Inc.

En fase 2b randomisert studie for å vurdere effektiviteten og sikkerheten til kombinasjonen av Ublituximab + Umbralisib med eller uten Bendamustine og Umbralisib alene hos pasienter med tidligere behandlet non-Hodgkins lymfom

Unity NHL - En randomisert fase 2b studie for å vurdere effektiviteten og sikkerheten ved kombinasjonen av Ublituximab + Umbralisib med eller uten Bendamustine og Umbralisib alene hos pasienter med tidligere behandlet non-Hodgkins lymfom

Studieoversikt

Detaljert beskrivelse

Hensikten med denne studien er å evaluere effektiviteten og sikkerheten til umbralisib monoterapi og umbralisib + ublituximab (U2) kombinasjonen ved aggressive og indolente lymfomer og å også utforske U2-regimet i kombinasjon med bendamustin i behandlingen av NHL (FL, SLL, MZL, DLBCL og MCL).

Studietype

Intervensjonell

Registrering (Faktiske)

710

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Gosford, Australia, 2076
        • TG Therapeutics Investigational Trial Site
    • New South Wales
      • Gosford, New South Wales, Australia, 02250
        • TG Therapeutics Investigational Trial Site
      • Wahroonga, New South Wales, Australia, 02076
        • TG Therapeutics Investigational Trial Site
    • Queensland
      • Benowa, Queensland, Australia, 04217
        • TG Therapeutics Investigational Trial Site
      • South Brisbane, Queensland, Australia, 04101
        • TG Therapeutics Investigational Trial Site
    • South Australia
      • Adelaide, South Australia, Australia, 05000
        • TG Therapeutics Investigational Trial Site
    • Victoria
      • Heidelberg, Victoria, Australia, 03084
        • TG Therapeutics Investigational Trial Site
    • Western Australia
      • Nedlands, Western Australia, Australia, 06009
        • TG Therapeutics Investigational Trial Site
      • Netherlands, Western Australia, Australia, 06009
        • TG Therapeutics Investigational Trial Site
    • Alabama
      • Birmingham, Alabama, Forente stater, 35243
        • TG Therapeutics Investigational Trial Site
      • Huntsville, Alabama, Forente stater, 35805
        • TG Therapeutics Investigational Trial Site
    • Arizona
      • Chandler, Arizona, Forente stater, 85224
        • TG Therapeutics Investigational Trial Site
      • Tucson, Arizona, Forente stater, 85711
        • TG Therapeutics Investigational Trial Site
      • Tucson, Arizona, Forente stater, 85724
        • TG Therapeutics Investigational Trial Site
    • California
      • Los Angeles, California, Forente stater, 90095
        • TG Therapeutics Investigational Trial Site
      • Orange, California, Forente stater, 92868
        • TG Therapeutics Investigational Trial Site
      • San Diego, California, Forente stater, 92108
        • TG Therapeutics Investigational Trial Site
      • San Diego, California, Forente stater, 90710
        • TG Therapeutics Investigational Trial Site
      • Whittier, California, Forente stater, 90603
        • TG Therapeutics Investigational Trial Site
    • Colorado
      • Aurora, Colorado, Forente stater, 80012
        • TG Therapeutics Investigational Trial Site
      • Denver, Colorado, Forente stater, 80218
        • TG Therapeutics Investigational Trial Site
      • Fort Collins, Colorado, Forente stater, 80528
        • TG Therapeutics Investigational Trial Site
    • Connecticut
      • Bridgeport, Connecticut, Forente stater, 06606
        • TG Therapeutics Investigational Trial Site
    • Delaware
      • Newark, Delaware, Forente stater, 19713
        • TG Therapeutics Investigational Trial Site
    • District of Columbia
      • Washington, District of Columbia, Forente stater, 20007
        • TG Therapeutics Investigational Trial Site
    • Florida
      • Boca Raton, Florida, Forente stater, 33486
        • TG Therapeutics Investigational Trial Site
      • Fort Myers, Florida, Forente stater, 33916
        • TG Therapeutics Investigational Trial Site
      • Gainesville, Florida, Forente stater, 32608
        • TG Therapeutics Investigational Trial Site
      • Jacksonville, Florida, Forente stater, 32224
        • TG Therapeutics Investigational Trial Site
      • Jacksonville, Florida, Forente stater, 32204
        • TG Therapeutics Investigational Trial Site
      • Jacksonville, Florida, Forente stater, 32256
        • TG Therapeutics Investigational Trial Site
      • Miami, Florida, Forente stater, 33176
        • TG Therapeutics Investigational Trial Site
      • Saint Petersburg, Florida, Forente stater, 33705
        • TG Therapeutics Investigational Trial Site
      • Tallahassee, Florida, Forente stater, 32308
        • TG Therapeutics Investigational Trial Site
      • Tampa, Florida, Forente stater, 33612
        • TG Therapeutics Investigational Trial Site
      • West Palm Beach, Florida, Forente stater, 33407
        • TG Therapeutics Investigational Trial Site
    • Georgia
      • Albany, Georgia, Forente stater, 31701
        • TG Therapeutics Investigational Trial Site
      • Macon, Georgia, Forente stater, 31201
        • TG Therapeutics Investigational Trial Site
      • Marietta, Georgia, Forente stater, 30060
        • TG Therapeutics Investigational Trial Site
    • Illinois
      • Chicago, Illinois, Forente stater, 60612
        • TG Therapeutics Investigational Trial Site
      • Chicago, Illinois, Forente stater, 60637
        • TG Therapeutics Investigational Trial Site
      • Decatur, Illinois, Forente stater, 62526
        • TG Therapeutics Investigational Trial Site
      • Evanston, Illinois, Forente stater, 60201
        • TG Therapeutics Investigational Trial Site
      • Harvey, Illinois, Forente stater, 60426
        • TG Therapeutics Investigational Trial Site
      • Maywood, Illinois, Forente stater, 60153
        • TG Therapeutics Investigational Trial Site
      • Niles, Illinois, Forente stater, 60714
        • TG Therapeutics Investigational Trial Site
      • Peoria, Illinois, Forente stater, 61615
        • TG Therapeutics Investigational Trial Site
      • Swansea, Illinois, Forente stater, 62226
        • TG Therapeutics Investigational Trial Site
    • Indiana
      • Fort Wayne, Indiana, Forente stater, 46845
        • TG Therapeutics Investigational Trial Site
      • Indianapolis, Indiana, Forente stater, 46237
        • TG Therapeutics Investigational Trial Site
    • Kansas
      • Westwood, Kansas, Forente stater, 66210
        • TG Therapeutics Investigational Trial Site
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40207
        • TG Therapeutics Investigational Trial Site
    • Louisiana
      • Covington, Louisiana, Forente stater, 70433
        • TG Therapeutics Investigational Trial Site
    • Maine
      • Brewer, Maine, Forente stater, 04412
        • TG Therapeutics Investigational Trial Site
    • Maryland
      • Baltimore, Maryland, Forente stater, 21201
        • TG Therapeutics Investigational Trial Site
      • Bethesda, Maryland, Forente stater, 20817
        • TG Therapeutics Investigational Trial Site
      • Columbia, Maryland, Forente stater, 21044
        • TG Therapeutics Investigational Trial Site
      • Towson, Maryland, Forente stater, 21204
        • TG Therapeutics Investigational Trial Site
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • TG Therapeutics Investigational Trial Site
    • Minnesota
      • Duluth, Minnesota, Forente stater, 55805
        • TG Therapeutics Investigational Trial Site
      • Saint Louis Park, Minnesota, Forente stater, 55416
        • TG Therapeutics Investigational Trial Site
    • Missouri
      • Columbia, Missouri, Forente stater, 65212
        • TG Therapeutics Investigational Trial Site
      • Kansas City, Missouri, Forente stater, 64132
        • TG Therapeutics Investigational Trial Site
      • Saint Louis, Missouri, Forente stater, 63110
        • TG Therapeutics Investigational Trial Site
    • Montana
      • Billings, Montana, Forente stater, 59102
        • TG Therapeutics Investigational Trial Site
    • Nebraska
      • Lincoln, Nebraska, Forente stater, 68510
        • TG Therapeutics Investigational Trial Site
      • Omaha, Nebraska, Forente stater, 68130
        • TG Therapeutics Investigational Trial Site
    • New Hampshire
      • Lebanon, New Hampshire, Forente stater, 03756
        • TG Therapeutics Investigational Trial Site
    • New Jersey
      • Hackensack, New Jersey, Forente stater, 07601
        • TG Therapeutics Investigational Trial Site
      • Morristown, New Jersey, Forente stater, 07962
        • TG Therapeutics Investigational Trial Site
      • Mount Holly, New Jersey, Forente stater, 08060
        • TG Therapeutics Investigational Trial Site
    • New Mexico
      • Farmington, New Mexico, Forente stater, 87401
        • TG Therapeutics Investigational Trial Site
    • New York
      • Bronx, New York, Forente stater, 10467
        • TG Therapeutics Investigational Trial Site
      • Buffalo, New York, Forente stater, 14263
        • TG Therapeutics Investigational Trial Site
      • New York, New York, Forente stater, 10019
        • TG Therapeutics Investigational Trial Site
      • Syracuse, New York, Forente stater, 13210
        • TG Therapeutics Investigational Trial Site
    • North Carolina
      • Charlotte, North Carolina, Forente stater, 28201
        • TG Therapeutics Investigational Trial Site
      • Durham, North Carolina, Forente stater, 27705
        • TG Therapeutics Investigational Trial Site
      • Hickory, North Carolina, Forente stater, 28602
        • TG Therapeutics Investigational Trial Site
      • Kinston, North Carolina, Forente stater, 28501
        • TG Therapeutics Investigational Trial Site
      • Raleigh, North Carolina, Forente stater, 27607
        • TG Therapeutics Investigational Trial Site
      • Washington, North Carolina, Forente stater, 27889
        • TG Therapeutics Investigational Trial Site
    • Ohio
      • Canton, Ohio, Forente stater, 44718
        • TG Therapeutics Investigational Trial Site
      • Cincinnati, Ohio, Forente stater, 45220
        • TG Therapeutics Investigational Trial Site
      • Cincinnati, Ohio, Forente stater, 45242
        • TG Therapeutics Investigational Trial Site
      • Cleveland, Ohio, Forente stater, 44106
        • TG Therapeutics Investigational Trial Site
      • Columbus, Ohio, Forente stater, 43219
        • TG Therapeutics Investigational Trial Site
      • Toledo, Ohio, Forente stater, 43623
        • TG Therapeutics Investigational Trial Site
    • Oregon
      • Portland, Oregon, Forente stater, 97227
        • TG Therapeutics Investigational Trial Site
      • Portland, Oregon, Forente stater, 97213
        • TG Therapeutics Investigational Trial Site
      • Springfield, Oregon, Forente stater, 97477
        • TG Therapeutics Investigational Trial Site
    • Pennsylvania
      • Camp Hill, Pennsylvania, Forente stater, 17011
        • TG Therapeutics Investigational Trial Site
      • Philadelphia, Pennsylvania, Forente stater, 19106
        • TG Therapeutics Investigational Trial Site
    • Rhode Island
      • Providence, Rhode Island, Forente stater, 02906
        • TG Therapeutics Investigational Trial Site
    • South Carolina
      • Greenville, South Carolina, Forente stater, 29615
        • TG Therapeutics Investigational Trial Site
    • South Dakota
      • Sioux Falls, South Dakota, Forente stater, 57105
        • TG Therapeutics Investigational Trial Site
      • Watertown, South Dakota, Forente stater, 57201
        • TG Therapeutics Investigational Trial Site
    • Tennessee
      • Chattanooga, Tennessee, Forente stater, 37404
        • TG Therapeutics Investigational Trial Site
      • Kingsport, Tennessee, Forente stater, 37660
        • TG Therapeutics Investigational Trial Site
      • Knoxville, Tennessee, Forente stater, 37916
        • TG Therapeutics Investigational Trial Site
      • Memphis, Tennessee, Forente stater, 38120
        • TG Therapeutics Investigational Trial Site
    • Texas
      • Austin, Texas, Forente stater, 78705
        • TG Therapeutics Investigational Trial Site
      • Dallas, Texas, Forente stater, 75390
        • TG Therapeutics Investigational Trial Site
      • Fort Sam Houston, Texas, Forente stater, 78234
        • TG Therapeutics Investigational Trial Site
      • Houston, Texas, Forente stater, 77030
        • TG Therapeutics Investigational Trial Site
      • San Antonio, Texas, Forente stater, 78229
        • TG Therapeutics Investigational Trial Site
      • San Antonio, Texas, Forente stater, 78217
        • TG Therapeutics Investigational Trial Site
      • San Antonio, Texas, Forente stater, 78130
        • TG Therapeutics Investigational Trial Site
      • Tyler, Texas, Forente stater, 75702
        • TG Therapeutics Investigational Trial Site
    • Utah
      • Ogden, Utah, Forente stater, 84403
        • TG Therapeutics Investigational Trial Site
    • Virginia
      • Blacksburg, Virginia, Forente stater, 24060
        • TG Therapeutics Investigational Trial Site
      • Newport News, Virginia, Forente stater, 23601
        • TG Therapeutics Investigational Trial Site
    • Washington
      • Olympia, Washington, Forente stater, 98502
        • TG Therapeutics Investigational Trial Site
      • Seattle, Washington, Forente stater, 98109
        • TG Therapeutics Investigational Trial Site
      • Seattle, Washington, Forente stater, 98104
        • TG Therapeutics Investigational Trial Site
      • Seattle, Washington, Forente stater, 98108
        • TG Therapeutics Investigational Trial Site
      • Spokane, Washington, Forente stater, 99216
        • TG Therapeutics Investigational Trial Site
      • Vancouver, Washington, Forente stater, 97277
        • TG Therapeutics Investigational Trial Site
    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53792
        • TG Therapeutics Investigational Trial Site
      • Wauwatosa, Wisconsin, Forente stater, 53226
        • TG Therapeutics Investigational Trial Site
      • Ashkelon, Israel, 7830604
        • TG Therapeutics Investigational Trial Site
      • Be'er Sheva, Israel, 8410101
        • TG Therapeutics Investigational Trial Site
      • Haifa, Israel, 91031
        • TG Therapeutics Investigational Trial Site
      • Jerusalem, Israel, 9112001
        • TG Therapeutics Investigational Trial Site
      • Nahariya, Israel, 2210001
        • TG Therapeutics Investigational Trial Site
      • Petah Tikva, Israel, 49100
        • TG Therapeutics Investigational Trial Site
      • Tel Aviv, Israel, 64239
        • TG Therapeutics Investigational Trial Site
      • Tel Aviv, Israel, 6971028
        • TG Therapeutics Investigational Trial Site
      • Bologna, Italia, 40138
        • TG Therapeutics Investigational Trial Site
      • Ferrara, Italia, 44020
        • TG Therapeutics Investigational Trial Site
      • Milan, Italia, 20132
        • TG Therapeutics Investigational Trial Site
      • Milan, Italia, 20141
        • TG Therapeutics Investigational Trial Site
      • Rome, Italia, 00161
        • TG Therapeutics Investigational Trial Site
      • Torino, Italia, 10126
        • TG Therapeutics Investigational Trial Site
      • Busan, Korea, Republikken, 47392
        • TG Therapeutics Investigational Trial Site
      • Busan, Korea, Republikken, 49241
        • TG Therapeutics Investigational Trial Site
      • Gyeonggi-do, Korea, Republikken, 13620
        • TG Therapeutics Investigational Trial Site
      • Incheon, Korea, Republikken, 21565
        • TG Therapeutics Investigational Trial Site
      • Seoul, Korea, Republikken, 03080
        • TG Therapeutics Investigational Trial Site
      • Seoul, Korea, Republikken, 06351
        • TG Therapeutics Investigational Trial Site
      • Seoul, Korea, Republikken, 06591
        • TG Therapeutics Investigational Trial Site
      • Chorzów, Polen, 41-500
        • TG Therapeutics Investigational Trial Site
      • Gdynia, Polen, 81-519
        • TG Therapeutics Investigational Trial Site
      • Kraków, Polen, 30-510
        • TG Therapeutics Investigational Trial Site
      • Lublin, Polen, 20-090
        • TG Therapeutics Investigational Trial Site
      • Słupsk, Polen, 76-200
        • TG Therapeutics Investigational Trial Site
      • Warszawa, Polen, 02-781
        • TG Therapeutics Investigational Trial Site
      • Warszawa, Polen, 02-106
        • TG Therapeutics Investigational Trial Site
      • Wrocław, Polen, 50-367
        • TG Therapeutics Investigational Trial Site
      • Łódź, Polen, 93-513
        • TG Therapeutics Investigational Trial Site
      • Bratislava, Slovakia, 81250
        • TG Therapeutics Investigational Trial Site
      • Bratislava, Slovakia, 83310
        • TG Therapeutics Investigational Trial Site
      • Košice, Slovakia, 04191
        • TG Therapeutics Investigational Trial Site
      • Poprad, Slovakia, 05801
        • TG Therapeutics Investigational Trial Site
      • Barcelona, Spania, 08035
        • TG Therapeutics Investigational Trial Site
      • Barcelona, Spania, 08041
        • TG Therapeutics Investigational Trial Site
      • Madrid, Spania, 28041
        • TG Therapeutics Investigational Trial Site
      • Madrid, Spania, 28222
        • TG Therapeutics Investigational Trial Site
      • Salisbury, Spania, 37007
        • TG Therapeutics Investigational Trial Site
      • Valencia, Spania, 46010
        • TG Therapeutics Investigational Trial Site
      • Cambridge, Storbritannia, CB2-0QQ
        • TG Therapeutics Investigational Trial Site
      • Denmark Hill, Storbritannia, SE5-9RS
        • TG Therapeutics Investigational Trial Site
      • Leeds, Storbritannia, LS97TF
        • TG Therapeutics Investigational Trial Site
      • Liverpool, Storbritannia, L7-8XP
        • TG Therapeutics Investigational Trial Site
      • London, Storbritannia, SW170QT
        • TG Therapeutics Investigational Trial Site
      • London, Storbritannia, EC1A-7BE
        • TG Therapeutics Investigational Trial Site
      • Oxford, Storbritannia, OX37LE
        • TG Therapeutics Investigational Trial Site
      • Plymouth, Storbritannia, PL68DH
        • TG Therapeutics Investigational Trial Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (VOKSEN, OLDER_ADULT)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inklusjonskriterier:

  • Diagnose av non-Hodgkins lymfom inkludert follikulært, mantelcellelymfom og marginalsone lymfom
  • Tilbakefall eller refraktær overfor tidligere standardbehandling og forsøkspersoner som ikke er kandidater for høydosebehandling eller autolog stamcelletransplantasjon
  • MCL-individer med én eller flere behandlingslinjer inkludert minst én BTK-hemmer (kun ibrutinib, acalabrutinib eller zanibrutinib)

Ekskluderingskriterier:

  • Enhver større operasjon, kjemoterapi eller immunterapi i løpet av de siste 21 dagene
  • Bevis på hepatitt B-virus, hepatitt C-virus eller kjent HIV-infeksjon
  • Autolog hematologisk stamcelletransplantasjon innen 6 måneder etter studiestart. Tidligere allogen hematologisk stamcelletransplantasjon er ekskludert
  • Tidligere behandling med en PI3K delta-hemmer

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: BEHANDLING
  • Tildeling: TILFELDIG
  • Intervensjonsmodell: PARALLELL
  • Masking: INGEN

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
EKSPERIMENTELL: Umbralisib + Ublituximab
Umbralisib oral daglig dose i kombinasjon med Ublituximab intravenøs administrering
Andre navn:
  • TG-1101
Andre navn:
  • TGR-1202
EKSPERIMENTELL: Umbralisib
Umbralisib oral daglig dose
Andre navn:
  • TGR-1202
EKSPERIMENTELL: Umbralisib + Ublituximab + Bendamustine
Umbralisib oral daglig dose i kombinasjon med Ublituximab intravenøs administrering og Bendamustine intravenøs administrering
Andre navn:
  • TG-1101
Andre navn:
  • TGR-1202
Andre navn:
  • Treanda

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Samlet svarfrekvens
Tidsramme: Hver 8.-12. uke, opptil 2 år
Hver 8.-12. uke, opptil 2 år

Sekundære resultatmål

Resultatmål
Tidsramme
Progresjonsfri overlevelse
Tidsramme: Fra dato for randomisering til dato for første dokumenterte progresjon, vurdert opp gjennom 2 år
Fra dato for randomisering til dato for første dokumenterte progresjon, vurdert opp gjennom 2 år

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studiestol: Owen A O'Connor, MD, PhD, Columbia University

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (FAKTISKE)

25. mai 2016

Primær fullføring (FAKTISKE)

31. mai 2022

Studiet fullført (FAKTISKE)

4. juli 2022

Datoer for studieregistrering

Først innsendt

23. mai 2016

Først innsendt som oppfylte QC-kriteriene

3. juni 2016

Først lagt ut (ANSLAG)

8. juni 2016

Oppdateringer av studieposter

Sist oppdatering lagt ut (FAKTISKE)

21. juli 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. juli 2022

Sist bekreftet

1. juli 2022

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Data vil bli delt når siste pasientbesøk er gjennomført

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere